BRISBANE, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the fourth quarter and year ended December 31, 2016.
“We have made significant recent progress and are very well-positioned for the launch of our exciting new product, AlloSure,” said Peter Maag, CareDx President and Chief Executive Officer. “With both pre- and post-transplant products encompassing the continuum of care, we have become a transplant-focused multiproduct genomic information company.”
